Sigma-Aldrich Corporation Logo


Committee Composition

Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member
  Audit Corporate Governance Compensation Science & Technology
Rebecca M. Bergman Member of Audit Committee     Member of Science & Technology Committee
Rebecca Bergman President of Gustavus Adolphus College

Ms. Bergman has more than 26 years of experience in the medical technology industry including over 18 years of experience in research and technology management and product development.  She is currently President of Gustavus Adolphus College, a liberal arts college located in St. Peter, MN.  Ms. Bergman served as Vice President, Research and Technology for Cardiac Rhythm Disease Management (“CRDM”) of Medtronic, Inc. (“Medtronic”), a manufacturer of products and therapies used in the diagnosis, treatment and monitoring of chronic conditions from 2012 to 2014, Vice President, New Therapies and Diagnostics for CRDM from 2009 to 2012, and Vice President, Science and Technology of Medtronic from 2002 to 2009.  Ms. Bergman has served as a member of the National Advisory Council of the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health and currently serves on a number of academic advisory boards.  Ms. Bergman is a Fellow of the American Institute for Medical and Biological Engineering and a member of the National Academy of Engineering.  She has a B.S. in Chemical Engineering from Princeton University and an honorary Ph.D. in Engineering from Drexel University.  She has also completed graduate studies in Chemical Engineering and Material Science at the University of Minnesota.  Age 57.


George M. Church, Ph. D.   Member of Corporate Governance Committee   Member of Science & Technology Committee
Professor of Genetics at the Harvard Medical School and Director of the Center for Computational Genetics in Cambridge, Massachusetts.

Dr. Church is a leading expert in human genetics and biotechnology and has significant academic research institution experience, having served as a Professor of Genetics at Harvard Medical School since 1986.  He concurrently acts as Director of the Center for Computational Genetics at Harvard Medical School, where he has directed laboratory research in DNA sequencing, synthesis and homologous recombination.  Dr. Church, an initiator of the Personal Genome Project in 2005 and a leader in the field of synthetic biology, is a director at the U.S. Department of Energy Center on Bioenergy at Harvard University, as well as the National Institutes of Health Center of Excellence in Genomic Science at Harvard University.  Dr. Church has served in scientific advisory roles for more than 20 companies in the field of DNA technology, diagnostics and biofuels.  He earned his Ph.D. in Biochemistry and Molecular Biology from Harvard University and his B.A. in Zoology and Chemistry from Duke University.  Age 59.


Michael L. Marberry Member of Audit Committee   Committee Chair for Compensation Committee  
President and CEO
J.M. Huber Corporation

Mr. Marberry has more than 31 years of management experience, including more than 16 years with J. M. Huber Corporation (“Huber”), a company that manufactures and sells products in the fields of specialty chemicals and engineered materials.  He has served as President and CEO since 2009.  Mr. Marberry served as President of Huber Engineered Materials, a division of Huber, from 2006 to 2009, CFO of Huber from 2002 to 2006, and Corporate Vice President of Strategy and New Business Development for Huber from 1997 to 2002.  Prior to joining Huber, he served in senior roles at M.A. Hanna Company, a specialty polymers company in Cleveland, Ohio, and in various roles with McKinsey & Company, Inc. and The Proctor and Gamble Company.  Mr. Marberry is an audit committee financial expert.  He is a director of Huber and a National Association of Corporate Directors (“NACD”) Governance Fellow.  Mr. Marberry earned his M.B.A. from Amos Tuck School of Business Administration at Dartmouth College and his M.S. and B.S. in Chemical Engineering from the University of Kentucky.  Age 55.





 


W. Lee McCollum Member of Audit Committee Committee Chair for Corporate Governance Committee    
W. Lee McCollum Former Executive Vice President & Chief Financial Officer
S.C. Johnson & Son, Inc.

Mr. McCollum has significant management experience including more than 35 years of experience with S.C. Johnson & Son, Inc. (“S.C. Johnson”), a global manufacturer and marketer of consumer products, where he held positions involving accounting, treasury, tax, internal audit, mergers and acquisitions, strategic planning, personnel matters, international operations and general management.  At S.C. Johnson, he served as Senior Vice President and CFO from 1997 to 2004 and as Executive Vice President and CFO from 2005 to 2009.  From 2005 to 2009, his responsibilities also included global manufacturing.  Mr. McCollum retired in 2009.  Mr. McCollum is also a director of Johnson Outdoors, Inc., Coastal South Bancshares, Inc. (Risk Management Committee Chair), and Johnson Financial Group, a large private regional bank holding company (Compensation Committee member, Risk Oversight Committee Chair).  Mr. McCollum is an audit committee financial expert.  He earned his M.B.A. from Harvard University and his B.S. from the University of Idaho.  Age 64.


Avi M. Nash Committee Chair for Audit Committee   Member of Compensation Committee  
Managing Director of Avi Nash LLC (Former partner of Goldman Sachs)

Mr. Nash has more than 36 years of experience in the chemical industry and in corporate finance and investing.  He is the Founder of Avi Nash LLC, a global management consulting firm that focuses on strategy, mergers and acquisitions and capital market transactions for the chemical industry, which he founded in 2003.  He also serves as Managing Director of Indian River Advisors Corporation, a financial advisory firm, since 2013.  Earlier, he was a partner of Goldman Sachs & Co. (“Goldman Sachs”), where he led the global chemical industry team in investment research, consistently topping performance rankings in the U.S. and globally.  At Goldman Sachs, Mr. Nash was appointed Vice President in 1989 and Managing Director in 1996, elected a partner in 1998 and named an advisory director in 2002.  Prior to Goldman Sachs, he gained over 10 years of experience involving strategy at Booz Allen and Hamilton, as well as R&D, engineering and marketing experience at UOP Inc., a developer of petroleum refining technology.  He has a Master of Management degree from Northwestern University, an M.S. degree in Chemical Engineering from Syracuse University and was named a distinguished alumnus of the Indian Institute of Technology, Mumbai, where he received a Bachelors degree in Chemical Engineering.  Mr. Nash is an audit committee financial expert.  Age 61.


Steven M. Paul, M.D.     Member of Compensation Committee Committee Chair for Science & Technology Committee
Director of the Appel Alzheimer's Disease Research Institute and Professor of Neurology, Psychiatry and Pharmacology at Weill Cornell Medical College

Dr. Paul is currently the Director of the Appel Alzheimer’s Disease Research Institute and a Professor of Neurology (Neuroscience), Psychiatry and Pharmacology at Weill Cornell Medical College of Cornell University.  He has more than 20 years of management experience in the pharmaceutical and biotechnology industries and 37 years of scientific research experience.  Dr. Paul retired in 2010 as Executive Vice President for Science and Technology and President of the Lilly Research Laboratories of Eli Lilly and Company (“Lilly”), a pharmaceutical company that engages in the discovery, development, manufacture and sale of pharmaceutical products, positions he held since 2003.  He joined Lilly in 1993 and served in roles of increasing responsibility within the Lilly research organization, including Vice President of Discovery Research and Clinical Investigation.  Prior to joining Lilly, Dr. Paul served in several senior roles at the National Institute of Mental Health, including serving as the Scientific Director of the Intramural Research Program.  He has authored or coauthored more than 500 papers and invited book chapters and serves on the editorial boards of numerous scientific journals and as a grant reviewer for several extramural and intramural committees.  He is a director of Alnylam Pharmaceuticals and a Venture Partner at Third Rock Ventures.  He is also a director of the Foundation of the National Institutes of Health, a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science.  Dr. Paul holds M.D., M.S. and B.A. degrees from Tulane University.  Age 63.


J. Pedro Reinhard   Member of Corporate Governance Committee Member of Compensation Committee  
J. Pedro Reinhard President of Reinhard & Associates (Former CFO, Dow Chemical Company)

Mr. Reinhard has more than 37 years of experience in the chemical industry and more than 32 years of international management experience, including more than 10 years as CFO of a publicly traded company.  He is an audit committee financial expert and has significant capital markets and finance experience.  Mr. Reinhard has served as President of Reinhard and Associates, a financial advisory practice, since 2006.  He served as Executive Vice President and CFO of The Dow Chemical Company (“Dow”), a manufacturer of chemicals, plastic materials, agricultural and other specialized products, from 1995 to 2005.  Previously, Mr. Reinhard held a variety of senior international, financial and operating leadership positions at Dow, including senior operations assignments in Europe, after beginning his career at Dow in 1970 in Brazil.  In 1988, he was appointed Treasurer of Dow.  Mr. Reinhard served as a director of Dow from 1995 to 2007.  Mr. Reinhard is also a director of Colgate Palmolive Co. and Royal Bank of Canada.  He earned his M.B.A. from Getulio Vargas University, São Paulo, and has done postgraduate work at the University of Cologne, Germany, and Stanford University.  Age 68. 


Rakesh Sachdev        
President and CEO

Mr. Sachdev has more than 28 years of management experience.  He has served as President and CEO of the Company since 2010.  Mr. Sachdev joined the Company in 2008 as Vice President and CFO and took on the additional role of Chief Administrative Officer and direct oversight of the Company’s international business in 2009.  He was Senior Vice President and President Asia Pacific of ArvinMeritor, Inc. (“ArvinMeritor”), a global supplier of parts and services to the automotive industry, from March 2007 to July 2008.  At ArvinMeritor, Mr. Sachdev also served in other leadership roles, including Interim CFO, Senior Vice President Strategy and Corporate Development and Vice President and General Manager of several of ArvinMeritor’s global businesses from February 1999 to March 2007.  Prior to joining ArvinMeritor, he worked for Cummins Inc., a global manufacturer of engines and other industrial products, in various leadership roles, including CFO for one of its largest business units, and as Managing Director of its Mexican operations.  Mr. Sachdev earned his M.B.A. from Indiana University, holds a Masters in Mechanical Engineering from the University of Illinois and earned his Bachelors degree in Mechanical Engineering from the Indian Institute of Technology in New Delhi.  Mr. Sachdev is also a director of Regal-Beloit Corporation and the Federal Reserve Bank of St. Louis and serves on the Board of Trustees of Washington University in St. Louis.  Age 58.


D. Dean Spatz   Member of Corporate Governance Committee   Member of Science & Technology Committee
Former Chairman and CEO, Osmonics, Inc.

Mr. Spatz has more than 45 years of management experience, including more than 32 years as CEO of a publicly traded company.  He currently serves as CEO of Watasso Ventures, a company that specializes in investing and actively participating in the management and development of entrepreneurial start-up companies, a position he has held since 2003.  In that capacity, he serves on the boards of four portfolio companies in various technical fields.  Previously, Mr. Spatz served as Chairman and Chief Executive Officer of Osmonics, Inc. (NYSE listed company), an international manufacturer and marketer of water purification, fluid separation and sea water handling products and equipment; a company he founded in 1969.  He left Osmonics in 2003 after the company was acquired by GE Infrastructure, a unit of General Electric Company.  Mr. Spatz is a licensed chemical engineer and is extensively published on reverse osmosis membrane technology, a breakthrough that he pioneered.  Mr. Spatz earned his M.S. in Engineering Management, B.S. in Engineering and B.A. from Dartmouth College.  Age 69.


Barrett Toan Chairman of the Board   Member of Corporate Governance Committee    
Barrett Toan Former Chairman and CEO of Express Scripts, Inc.

Mr. Toan has more than 32 years of healthcare industry experience and more than 29 years of management experience, including more than 20 years as a CEO.  He served as Chairman of Express Scripts, Inc. (“Express Scripts”), a pharmacy benefits management company, from 1996 to 2006 and as President and CEO of Express Scripts from 1989 until his retirement in 2005.  As President and CEO, Mr. Toan led the Express Scripts initial public offering in 1992, deployed innovative cost-savings and patient safety programs and led the company’s growth into a Fortune 500 firm.  Prior to joining Express Scripts, he was the Chief Operating Officer and Executive Director of Sanus Corps Health Systems Inc. (later GenCare) (“Sanus”), a leading health maintenance organization.  Before joining Sanus, Mr. Toan served in the public sector in a variety of roles, including the Director of Missouri’s Department of Social Services.  Mr. Toan earned his M.B.A. from The Wharton School of the University of Pennsylvania and his A.B. from Kenyon College.   Age 66.